Overview
This study is an observational, multicenter and prospective study for surveillance of case of hospitalised children for bronchiolitis associated or not to RSV or other viruses (isolated or associated with RSV)
Description
The aim of this surveillance is to observe and describe the cases hospitalized for bronchiolitis in the 2023/2024 season in the context of routine immunization with Nirsevimab.
Eligibility
Inclusion Criteria:
- Children under 12 months of age
- In one of the 6 study sites
- From October 15, 2023
- For acute bronchiolitis defined according to current national and international recommendations
- Hospitalized from the pediatric emergency department.
Exclusion Criteria:
- Refusal to participate by patient relative or legal representative